-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, Johnson & Johnson Reports 57% Of Psoriatic Arthritis Patients With Qualifying Skin Involvement On ICOTYDE Achieved Clear Or Almost Clear Skin Versus 14% On Placebo, Alongside 58% ACR20 Response At Week 16

Benzinga·11/09/2026 08:39:42
Listen to the news
  • Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16
  • ICOTYDE is a first-in-class IL-23R targeted oral peptide, demonstrating significant joint and skin improvements and a favorable safety profile in a once-daily pill